SCHEMBL176950

SCHEMBL176950

Br[Mg]C1CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6064 0.92
SCHEMBL11144949 0.89 ALDH1A1 (0.30)
SCHEMBL120534 0.89
SCHEMBL2646596 0.89 ALDH1A1 (0.30)
SCHEMBL11148671 0.89 ALDH1A1 (0.30)
Water SCHEMBL2062906 0.89
Water SCHEMBL10976746 0.86
SCHEMBL12001 0.84
Formic Acid SCHEMBL30744059 0.83
Ether SCHEMBL3110293 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 376 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119930381-A Synthesis method of Z-configuration chiral olefin 深圳连续制药科技有限公司 2025-05-06 CN claimed
CN-116217319-B Method for desymmetrizing reaction of meso allyl ether 哈尔滨工业大学(深圳) 2025-02-11 CN claimed
CN-118373723-A Asymmetric alkylation reaction method of chain racemization allyl ether 哈尔滨工业大学(深圳)(哈尔滨工业大学深圳科技创新研究院) 2024-07-23 CN claimed
CN-116217319-A Method for desymmetrizing reaction of meso allyl ether 哈尔滨工业大学(深圳) 2023-06-06 CN claimed
EP-0885218-B1 OXA- AND THIA-DIAZOLE MUSCARINIC RECEPTOR ANTAGONISTS PFIZER RES AND (IE) 2001-05-02 EP claimed
US-5977142-A Oxa-and thia-diazole muscarinic receptor antagonists PFIZER INC. (US) 1999-11-02 US claimed
EP-0885218-A1 OXA- AND THIA-DIAZOLE MUSCARINIC RECEPTOR ANTAGONISTS Pfizer Research and Development Company, N.V./S.A. (IE) 1998-12-23 EP claimed
WO-1997030994-A1 OXA- AND THIA-DIAZOLE MUSCARINIC RECEPTOR ANTAGONISTS PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) 1997-08-28 WO claimed
EP-4741018-A2 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2026-05-13 EP disclosed
US-12583836-B2 Sulphonamide compounds Anaxis Pharma Pty Ltd (AU) 2026-03-24 US disclosed
EP-4709481-A1 5,6-FUSED AND 6,6-FUSED BICYCLIC ALCOHOLS AND ETHERS AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS Amgen Inc. (US) 2026-03-18 EP disclosed
US-12551490-B2 Heterocyclic modulators of lipid synthesis SAGIMET BIOSCIENCES INC. (US) 2026-02-17 US disclosed
US-20260028336-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2026-01-29 US disclosed
US-20260028356-A1 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS ABBVIE INC (US) 2026-01-29 US disclosed
CN-1168377-A Novel buprenophine analgesic analogues DONG KOOK PHARM CO LTD (KR) 1997-12-24 CN disclosed
US-5354758-A Brain and nervous system disorders JAPAN TOBACCO INC. (JP) 1994-10-11 US disclosed
EP-0530994-A1 Quinazoline derivatives as inhibitors of HIV reverse transcriptase MERCK & CO. INC. (US) 1993-03-10 EP disclosed
WO-1993004047-A1 QUINAZOLINE DERIVATIVES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE MERCK & CO., INC. (US) 1993-03-04 WO disclosed
US-4328233-A α-Glucosidase inhibiting 2-hydroxymethyl-3,4,5-trihydroxy-piperidines BAYER AKTIENGESELLSCHAFT (DE) 1982-05-04 US disclosed
EP-0010745-A1 2-Hydroxymethyl-3,4,5-trihydroxy-piperidine derivatives, their preparation and medicaments containing them BAYER AG (DE) 1980-05-14 EP disclosed